Hetero Labs filed an application with the Central Drugs Standard Control Organisation (CDSCO) last week. The CDSCO may soon reach out to ICMR for suggestions.
In science, establishing that something doesn’t work is as crucial as finding a solution. This is why most Covid-19 clinical trials are repurposing existing drugs.
Cipla, Hetero Labs, Jubilant Lifesciences & Mylan have now been allowed by remdesivir’s patent holder, Gilead, to produce the drug that has shown promise in Covid-19 treatment.
Under the licensing agreement, Jubilant will have the right to receive a technology transfer of the manufacturing process to scale up remdesivir production.
Drug has shown benefits in reducing recovery time for some patients, and the govt has asked companies if they’re in touch with Gilead Sciences for a licence.
Gilead Sciences plans a global consortium of pharma firms for production. It says decision of partnership will depend on how fast the drug’s supply can be ramped up.
Indian judiciary has a corrosive imbalance between the bar and the bench. Those who supervise the district judiciary do so without the lived experience that is essential for meaningful reform.
November exports to the US saw 10% growth from the previous month. Overall, in the first 8 months this fiscal, the merchandise exports to the US touched has touched $59bn.
Of the total package, $649 million will be utilised for additional hardware, software, and support services, and the remaining for Major Defence Equipment (MDE).
Don’t blame misfortune. This is colossal incompetence and insensitivity. So bad, heads would have rolled even in the old PSU-era Indian Airlines and Air India.
Hii I need a remdesivir 100 mg I.v